CDMO turnaround may be delayed
CDMO performance remained soft in Q2; management expects rebound in H2 but any delay in project ramp-ups or regulatory approvals could impact growth.
ALIVUS / Q2-FY26 / risks
Keep the risk register visible.
Alivus Life Sciences · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
GPL recovery uncertain
GPL segment declined due to customer inventory rationalization; management expects recovery in H2 but could not quantify, leaving uncertainty.
Capex delays may constrain future growth
Capex spend has been slower than planned; while management says it won't impact near-term growth, delays in capacity expansion could limit medium-term scalability.
Regulatory compliance incident at Gujarat plant
A flash fire led to a penalty from the Gujarat State Pollution Control Board; while management downplays it, repeated issues could affect operations.